United States v. Rollow

146 F. App'x 290
CourtCourt of Appeals for the Tenth Circuit
DecidedAugust 22, 2005
Docket03-6094
StatusUnpublished
Cited by5 cases

This text of 146 F. App'x 290 (United States v. Rollow) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Rollow, 146 F. App'x 290 (10th Cir. 2005).

Opinion

ORDER AND JUDGMENT *

McWILLIAMS, Senior Circuit Judge.

In a 47-count Indictment filed in the United States District Court for the Western District of Oklahoma, Shirley Maye Rollow (“Rollow”), Norma El-Samad (“El-Samad”), Lorraine Bourassa (“Bourassa”), and Hung Nguyen (“Nguyen”), were charged with various drug and drug related crimes. From the “Introduction” section in the indictment we learn that pseudoephedrine is a listed chemical under the Controlled Substances Act and is made to be used as an over-the-counter sinus medication, but that it can also be used as a primary ingredient in the manufacture of methamphetamine, a controlled substance. We further learn that because pseudoephedrine is a listed chemical, manufacturers and distributors of pseudoephedrine are required to be registered with the Drug Enforcement Administration and are further required to maintain records of their purchase and distribution of pseudoephedrine. Thus, those who seek to be distributors of pseudoephedrine must identify the customers to whom they sell pseudoephedrine. El-Samad was an owner and operator of a company named Norma’s Enterprises in Oklahoma City, Oklahoma. Bourassa was an owner and operator of a company named Southwest Sales in Arlington, Texas. Rollow was an employee of both Norma’s Enterprises and Southwest Sales. Nguyen was also an employee of both companies.

In the first count of the indictment, all four defendants were charged with con *292 spiring from January 1999 to July 2001, with each other, and others, to possess and distribute pseudoephedrine, a listed chemical, knowing or having reasonable cause to believe that the pseudoephedrine would be used to manufacture methamphetamine, in violation of 21 U.S.C. § 841(c)(2). In Counts 39 through 47 Rollow was charged with “Structuring Transactions to Avoid Reporting Requirements,” in violation of 31 U.S.C. §§ 5324(a)(3), and 5322(b). Collectively, those transactions were claimed to total some $50,000. The United States also sought forfeiture under 21 U.S.C. § 853.

Rollow and El-Samad were thereafter jointly tried. Bourassa had entered into a plea agreement and testified as a government witness at the trial. Nguyen, who had been released on bail, absconded and was not tried with Rollow and El-Samad. Nguyen was later apprehended and he then entered into a plea agreement with the government. Rollow was convicted on Count 1, and Counts 39 through 47, (excepting Count 44, which was consolidated with Count 43) and was sentenced to 180 months on Count 1, and 60 months on each of the remaining counts, all to be served concurrently. 1

At trial, it was the government’s theory of the case that Rollow and the other defendants had conspired with each other, and others, to distribute pseudoephedrine “knowing or having reasonable cause to believe that the pseudoephedrine would be used to manufacture methamphetamine.” It was Rollow’s theory of the case that her acquisition and distribution of the pseudoephedrine was “innocent,” i.e., that she did not know or have reason to know that her distributees would use the pseudoephedrine to manufacture methamphetamine, that, in fact, she thought her distributees were going to sell the pseudoephedrine as a cold remedy, and that she did not “conspire” with anyone.

At oral argument, counsel for Rollow presented two grounds for reversal: (1) the district court improperly admitted evidence showing that in June, 2001, Rollow had stored ten million pseudoephedrine tablets in Curaao, Netherlands Antilles, which she proposed to ultimately bring into the United States, and (2) the district court erred in its sentencing of her.

Rollow filed a motion in limine attempting to obtain an order of the court that any evidence showing that Rollow had stored ten million pseudoephedrine tablets in Curaao would not be admitted at trial. The district court conditionally denied Rollow’s motion, stating that if the government’s evidence at trial was the same as represented to the court at the hearing, the testimony regarding Rollow’s storing ten million pseudoephedrine tablets would be admitted at trial. In so doing, the district court stated that its order was not based on Federal Rules of Evidence 404(b), but was based on its belief that the testimony regarding the pseudoephedrine stored in Curaao was a part and parcel of the conspiracy charged in Count 1 of the indictment. In this general connection, the court spoke as follows:

“If the evidence is developed at trial along the lines stated in Mr. Sengel’s brief and presentation just heard, it would be relevant with respect to the conspiracy charge because of efforts to obtain alternate sources of the substance, pseudoephedrine. And that would not be 404(b) evidence because *293 it’s inherent in the Count One of the indictment. If that’s not the way the evidence develops and we hear references to that, why, the government’s in a bit of trouble ...”

Additionally, the district court also spoke as follows:

With respect to the matter of Curaao as a source, and whether permits would be required to bring pseudoephedrine from Curaao into the United States, there’s nothing about this conspiracy that requires illegality with respect to the source. Actually, Summa is a perfectly legal source. And the offense could be committed just as easily by a lawful import from Curaao as an unlawful import from Curaao because all that matters is what happens when it gets here.

We find no error in the admission of testimony showing that in June, 2001, Rollow had ten million pseudoephedrine tablets in storage in Curaao and that she was contemplating removal of those tablets to the United States. The indictment alleged a conspiracy from January, 1999, to July, 2001, and the evidence was that the Curaao “storage” was as of June, 2001. There was evidence, as was mentioned by the district court, that the defendants’ source of pseudoephedrine in Texas was “drying up,” and that the defendants were looking for “alternative sources.” The testimony of Charles Mustin, Lorraine Bourassa, and an audio tape recording of a telephone conversation between Rollow and one Tan Do concerning the pseudoephedrine belonging to Rollow and stored in Curaao was sufficient to indicate, prima facie, that such was within the scope of the conspiracy charged in Count 1.

As for the audio tape of the telephone conversation between Rollow and Tan Do, counsel complains that because the government had allowed Tan Do to be free on bail, and he thereafter absconded, Rollow was denied her right to cross examine Tan Do. He suggests that the government conspired with Tan Do to abscond and thus to be unavailable at Rollow’s trial. In that connection, there is no evidence of government misconduct, only the suggestion of counsel.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Rollow
Tenth Circuit, 2009
United States v. Rollow
357 F. App'x 966 (Ninth Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
146 F. App'x 290, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-rollow-ca10-2005.